Spleen Dose-Volume Parameters as a Predictor of Treatment-related Lymphopenia During Definitive Chemoradiotherapy for Esophageal Cancer

Our study sought to identify dosimetric predictors of treatment-related lymphopenia during chemoradiotherapy for esophageal cancer. Patients with esophageal cancer who had received definitive chemoradiotherapy at our Institution were retrospectively assessed. The absolute volume of the spleen, body,...

Full description

Saved in:
Bibliographic Details
Published inIn vivo (Athens) Vol. 32; no. 6; pp. 1519 - 1525
Main Authors Saito, Tetsuo, Toya, Ryo, Yoshida, Naoya, Shono, Takashi, Matsuyama, Tomohiko, Ninomura, Satoshi, Watakabe, Takahiro, Sasaki, Yutaka, Baba, Hideo, Oya, Natsuo
Format Journal Article
LanguageEnglish
Published Greece International Institute of Anticancer Research 01.11.2018
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Our study sought to identify dosimetric predictors of treatment-related lymphopenia during chemoradiotherapy for esophageal cancer. Patients with esophageal cancer who had received definitive chemoradiotherapy at our Institution were retrospectively assessed. The absolute volume of the spleen, body, and bone marrow that had received 5, 10, 20, and 30 Gy and the mean splenic dose were recorded. Multivariate linear regression analysis revealed that docetaxel use and spleen dose-volume parameters (V5, V10, V20, V30, and mean splenic dose) were significant independent factors negatively influencing the absolute lymphocyte count at nadir. An increase of 1 Gy in mean splenic dose predicted a 2.9% decrease in nadir absolute lymphocyte count. Univariable logistic regression analysis showed that the mean splenic dose was a significant predictor of grade 4 lymphopenia. None of the body or bone marrow dose-volume parameters significantly predicted lymphopenia. Higher spleen dose-volume parameters were associated with severe lymphopenia during chemoradiotherapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0258-851X
1791-7549
DOI:10.21873/invivo.11409